Back to top
more

Praxis Precision Medicines (PRAX)

(Real Time Quote from BATS)

$50.55 USD

50.55
78,456

+1.71 (3.50%)

Updated Apr 24, 2024 03:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PRAX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Praxis Precision Medicines, Inc. [PRAX]

Reports for Purchase

Showing records 1 - 20 ( 98 total )

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

04/08/2024

Company Report

Pages: 7

Layering In The Financing, New $40 Target

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/26/2024

Daily Note

Pages: 4

Lighting Things Up With PRAX-628, But We''re Waiting For P2b Data

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 10.00

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

03/22/2024

Industry Report

Pages: 10

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

03/06/2024

Company Report

Pages: 5

After a Productive 2023, 2024 Should Be a Banner Year for Praxis

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

03/05/2024

Company Report

Pages: 8

PPR Update Comes Next (1Q24), As ET Efforts Progress

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

02/06/2024

Daily Note

Pages: 7

Preliminary PPR Results For 15mg Cohort Provide a Win; What We''re Looking for Next

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 25.00

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

01/31/2024

Daily Note

Pages: 114

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

01/30/2024

Daily Note

Pages: 115

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

01/12/2024

Daily Note

Pages: 7

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

01/12/2024

Company Report

Pages: 7

Adding The Financing; Removes Cash Runway Overhang But Sticking With Sidelines

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

01/09/2024

Daily Note

Pages: 3

PRAX-628 Shows a Signal in PPR Study; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 10.00

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

01/08/2024

Daily Note

Pages: 5

Praxis Monetizes Ulixa China Opportunity; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

12/05/2023

Daily Note

Pages: 3

Additional AES Takeaways; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

12/04/2023

Daily Note

Pages: 4

Live From AES: PRAX-222 Continues To Show Compelling Results

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 5.00

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

11/30/2023

Company Report

Pages: 8

Differentiated Epilepsy Should Shine at Upcoming AES Meeting; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

11/29/2023

Company Report

Pages: 7

Adjusting PT, EPS Estimates Following 1-For-15 Reverse Stock Split

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 12.50

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

11/15/2023

Company Report

Pages: 6

Competitor''s Recent FOS Phase 2 Failure Validates Praxis'' Approach with ''628; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/07/2023

Company Report

Pages: 8

With ET Phase 3 Efforts Underway, Focus Remains On Execution [3Q23 Highlights]

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 12.50

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

10/03/2023

Daily Note

Pages: 10

RD Day Event Shines Light on ET Phase 3 Plans, Early PRAX-222 Data

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 12.50

Research Provided by a Third Party

Company: Praxis Precision Medicines, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

10/03/2023

Daily Note

Pages: 10

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party